via Tokyo University of Science
Scientists modified “mesenchymal stem cells” to carry anti-cancer drugs and deliver them to target cancers
Targeting drugs to cancer tissues is a major challenge in cancer treatment. Mesenchymal stem cells (MSCs) are known for their ability to find and target tumor cells in the body, but using MSCs for drug delivery has been tricky, because upon loading with drugs, MSCs lose their viability and migratory ability. Now, researchers from Tokyo University of Science have successfully modified MSCs to deliver large quantities of anti-cancer drugs in a targeted manner to developing cancer cells.
As humans evolve, cancer also evolves in parallel, making the race for finding efficient treatment methods for cancer patients challenging and constant. In addition to designing drugs for treatment, the delivery of these drugs to targeted organs is also a major challenge faced by the cancer research community.
Many research groups have tried to develop techniques to efficiently deliver anti-cancer drugs to tumors. An interesting way utilizes a distinct group of cells in our body, the mesenchymal stem cells (MSCs), which have a special ability to find and move towards tumors. This means that theoretically, we can load these “tumor-homing” MSCs with anti-cancer drugs and use them to hinder cancer progression. However, pilot studies show that the anti-cancer drug loading capacity of MSCs is limited, and they tend to lose their ability to target and reach tumor cells upon drug loading.
In a recent study published in Journal of Controlled Release, researchers from Japan, led by Dr. Kosuke Kusamori and Professor Makiya Nishikawa from Tokyo University of Science, sought to find out how to modify MSCs to bypass these problems. Dr. Kusamori, Assistant Professor in the University’s Department of Pharmacy says, “We wondered if the answer to our dilemma of modifying mesenchymal stem cells with an anticancer drug was to exploit the property of mesenchymal stem cells to accumulate in tumor tissues.”
Using the well-known “avidin-biotin complex” (ABC) method, the researchers used liposomes-cellular lipid bags popularly used as drug delivery systems-to carry the anti-cancer drug doxorubicin (DOX) to the surface of specific mouse MSCs. They named these lipid bags carrying DOX “DOX-Lips.”
The researchers found that the MSCs loaded with DOX-Lips could carry and selectively target mouse colon cancer cells growing in artificial cultures in the lab. These modified MSCs could not only carry a significant amount of the drug, but also efficiently deliver it inside the target cancer cells. To test if this feature is replicated in a living system, they used a mouse model with skin and lung cancer. They found that in both cases, DOX-Lips were able to efficiently reach cancer cells and release the drug into the cytoplasm of the cancer cells. The researchers concluded that the modified MSCs could completely suppress tumor growth in mouse models.
There are several advantages to this new method. First, the process is relatively faster than previously known methods. As Yukiya Takayama, a doctoral student in Professor Nishikawa’s lab and a co-author of the study observes, “The relatively short duration of the ABC method made it possible to quickly modify the cell surface with DOX-Lips and avoid cell damage.”
Second, this method did not affect the process of cell attachment to cancer cells, thereby ensuring maximum efficiency in drug delivery. Third, contrary to previous observations that lipid bags of only a certain size can be used to deliver drugs, this new study suggests that the size of the lipid bags very likely does not affect drug delivery; this finding can be exploited to deliver many different doses of drugs as well.
The combination of the ABC method and the use of Lips thus seems to be the answer to the researchers’ dilemma. Professor Nishikawa is excited about these results. “We have succeeded in developing a new targeted cancer therapy,” he observes. “Mesenchymal stem cells can migrate to brain tumors and minute cancer lesions that are otherwise inaccessible to conventional drug delivery systems. Our method may thus be effective against intractable cancers,” Nishikawa says.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Modified stem cells
- Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantationon April 29, 2021 at 10:58 am
Although graft failure (GF) is a fatal complication after allogeneic (SCT), no mortality risk assessments after salvage SCT have been reported. We developed a comprehensive prognostic scoring system ...
- Surface Modified β-Tricalcium phosphate enhanced stem cell osteogenic differentiation in vitro and bone regeneration in vivoon April 29, 2021 at 6:04 am
A major number of studies have demonstrated Beta-tricalcium phosphate (β-TCP) biocompatibility, bioactivity, and osteoconductivity characteristics in bone regeneration. The aim of this research was to ...
- Why can’t humans regrow limbs like an axolotl or a lizard?on April 28, 2021 at 12:51 pm
This hints at a possibility that we have inherited the ability to regenerate limbs, yet the relevant bits of genetic code may be switched off or modified ... cells, like embryonic cells or stem ...
- Celularity: Productizing Placental-Derived Stem Cells for Any Patienton April 28, 2021 at 12:32 pm
GEN Edge spoke with Robert Hariri, MD, PhD, the chairperson, founder, and CEO of Celularity, to discuss the company’s 20-year journey from inception to Celgene spinoff and, recently, a special purpose ...
- Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meetingon April 27, 2021 at 1:40 pm
Two Oral Presentations to Cover iPSC-derived Cell-based Cancer Immunotherapy Pipeline Company to Host Investor Event on May 13 to Highlight ...
Go deeper with Google Headlines on:
Modified stem cells
Go deeper with Bing News on:
Mesenchymal stem cells
- Biopharma Study Shows Safety of Stem Cell Therapy in Severe COVID-19 Patientson April 29, 2021 at 11:32 am
(SRNE:NASDAQ) completed its Phase 1b MSC-COV-101 trial of COVI-MSC, allogeneic adipose-derived mesenchymal stem cells, as a treatment for COVID-19-induced acute respiratory failure (ARD) and acute ...
- Sugar Land nonprofit's revolutionary stem cell treatment yields 'no sign of disease' in Parkinson's patientson April 28, 2021 at 12:33 pm
A promising study from a Sugar Land-based non-profit research organization has shown significant improvement in Parkinson’s Disease patients with the use of stem cell treatment. Hope Biosciences Stem ...
- Stem Cell Therapy Market worth $401 million by 2026 - Exclusive Report by MarketsandMarkets™on April 28, 2021 at 5:30 am
According to the new market research report "Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic ...
- FDA Authorizes Novel Stem Cell Trial for Parkinson’son April 27, 2021 at 9:00 pm
Hope Biosciences Stem Cell Research Foundation Receives FDA Authorization for Parkinson's Disease Phase II Trial ...
- Stem cell transplant can help kids with autism says experton April 24, 2021 at 7:05 pm
Director of Bentoluene International Health Concept, Ogunleye Tolulope, has said that grouping of stem cell transplant, therapy ...